Background. A staging/prognostic system has long been desired to better categorize pheochromocytoma/ paraganglioma which can be very aggressive in the setting of SDHB mutations. Methods. A retrospective analysis was conducted of clinical characteristics and outcomes including results of genetic testing, tumor recurrence/metastasis, Ki67/MIB1% staining, and tumor mitotic index in patients with pheochromocytoma/paraganglioma. Results. Patients with SDHB mutation presented at younger age (33.0 years old vs 49.6 years old, P < .001), had increased local recurrence and distant metastases (47.6% vs 9.1%, P < .001, and 56.3% vs 9.1%, P < .001, respectively), and lesser median disease-free interval (89.8 months, 95% confidence interval 36.0-96.4 vs not reached, P < .001). SDHB mutation, greatest tumor diameter, and open operative resection were associated with a greater rate of local recurrence and distant metastases (P < .006 each). SDHB mutation and tumor diameter were independent risk factors for local recurrence (P # .04 each) and metastases. Ki67% and mitotic index were not associated with SDHB mutation (P $ .09 each), local recurrence (P = .48, P = .066, respectively), metastases (P $ .22 each), or disease-free interval (P $ .19 each). Conclusion. SDHB status and primary tumor size are more predictive of patient outcome than Ki67% or mitotic index and should be part of any clinically relevant, prognostic scoring system. (Surgery 2017;161:230-9.) 
recurrence, distant metastases, and disease-specific mortality. 7 Differentiating between benign and malignant PC/PGL is critical for optimized patient care. Resection is the mainstay of treatment for primary neoplasms, can be applied to locoregional disease or recurrences, and may be palliative in patients with functioning distant metastases. 8 There is no widely used staging or prognostic scoring system for PC/PGL. Studies on prognostic factors associated with PC/PGL have shown the presence of SDHB mutation, primary tumor size, and age at diagnosis to be significant prognostic factors. 9 Previously described staging systems based on pathologic data such as the pheochromocytoma of the adrenal gland scaled score have been associated with patient outcome in small cohort studies but have not been validated. [10] [11] [12] [13] [14] The grading system for adrenal PC and PGL utilizing pathology findings to create a scoring system has also been proposed, because it was associated with patient outcome in one study. 15 No current grading system includes genetic mutation status, despite the greater risk of recurrence, metastases, and mortality, especially in patients with germline SDHB mutations. An improved staging/prognostic system has long been desired to better categorize PC/PGL, which could allow for better treatment selection and improve prognostication and follow-up measures.
To our knowledge, no previous study has analyzed germline mutation status, tumor type, size, functionality, and histologic features, such as Ki67/MIB-1% and mitotic index (MI), simultaneously. In this study, we performed a comprehensive analysis of genetic, clinical, biochemical, and histologic variables in patients with localized PC/ PGL to test the hypothesis that there are prognostic factors in patients with localized PC/PGL.
METHODS
A retrospective analysis was conducted in patients with germline testing confirming SDHB mutation status and PC or abdominal/pelvic PGL who were treated at our institution from 1998-2015. All patients were enrolled in a clinical protocol after written informed consent, and the studies were approval by the Office of Human Subject Research at the National Institutes of Health. All patients included in the study were tested for known germline mutations, including SDHx, RET, VHL, NF1, and MAX. Of 256 patients with PC or abdominal/pelvic PGL, 49 carried SDHB mutations. Of 73 patients considered to have sporadic disease based on a negative germline testing result and no family history, 35 were selected randomly as a comparison cohort.
Clinical characteristics, including age, sex, mutation status, and tumor characteristics of the disease, including location, functional status, and size based on pathology, were reviewed. Surgical data, including operative approach, were analyzed. The decision for a specific operative approach was multifactorial and based on mutation status, tumor type, and tumor size. A majority of patients with SDHB mutation, PGL, larger tumors, or a contraindication to laparoscopic operation had an open approach. Treatment outcomes, including local recurrence, distant metastases, disease-free interval (DFI), and disease-specific death, were also analyzed in all patients.
DFI was defined as time after R0 resection with no evidence of local recurrence or distant metastasis on anatomic imaging (whole body computed tomography [CT]/magnetic resonance imaging), functional imaging (18F-FDG positron emission tomography/CT, 18F-FDOPA positron emission tomography/CT), and biochemical testing (serum and urine catecholamine and metanephrines and serum chromogranin A). For patients who were never disease-free, DFI was defined as zero. Patients were followed from the date of their operation until the date of recurrence (local or distant), last follow-up, or death. Pathologic data, including greatest primary tumor size, were analyzed in all patients.
Primary tumor samples when available were stained and analyzed for Ki67/MIB-1% staining and MI. PC and PGL tumor specimens were reexamined by 2 pathologists independently who were blinded to the clinical follow-up data. Mitotic count was assessed based on examination of 50 high power fields (HPF). MI count was analyzed as 0 mitoses, 1 mitoses, or $2 mitoses per HPF. Immunohistochemical stains for MIB-1/Ki-67 (anti-human Ki-67 monoclonal mouse antibody at 1:200 dilution, [Dako M7240, Carpinteria, CA]) were performed on available, formalin-fixed, paraffin-embedded tissue sections, using an automated immunostainer following the manufacturer's specifications. MIB-1 labeling index was based on the examination of 2 HPF (40X) demonstrating the greatest staining, and the percent of positive tumor cells was scored as <1%, 1-3%, and > 3% (Fig 1) .
Associations between 2 dichotomous parameters were determined by the Fisher exact test, while the association between an ordered categorical parameter and a dichotomous parameter was determined by an exact Cochran-Armitage test for trend. The association between a dichotomous parameter and a continuous parameter was determined by an exact Wilcoxon rank-sum test. The Kaplan-Meier method was used to determine the probability of recurrence as a function of time. The statistical significance of the difference among curves was determined using a log-rank test. The factors that demonstrated association with time to recurrence in the univariate analyses were evaluated subsequently for their joint association with time to recurrence using a Cox proportional hazards model. All P values are 2-tailed and reported without adjustment for multiple comparisons.
RESULTS
A total of 84 patients treated at the National Institutes of Health clinical center for PC/PGL were included in the study; 49 patients had germline SDHB mutations, and 35 patients had sporadic disease. The clinical, biochemical, and genetic characteristics and treatments used in the study cohort are summarized in Table I . Sixty-five patients with isolated local disease underwent complete resection of their primary tumor with negative margins (R0).
Thirteen patients with the primary resection performed at an outside institution underwent resection of locoregional recurrences and/or isolated distant metastases. Three patients underwent resection of their primary tumors with synchronous metastases also treated with resection or external beam radiation. Three patients presented with extensive metastatic disease and were treated with cisplatin, vincristine, and doxorubicin. The follow-up time for the sporadic group of patients and for patients with SDHB mutations was 58.2 ± 8.5 months vs 95.9 ± 16.7 months, respectively (P = .29). There were no perioperative deaths.
Patients with SDHB mutations presented at a younger age compared with patients without SDHB mutation (33.0 ± 2.3 years vs 49.6 ± 2.1 years, respectively, P < .001). Patients with SDHB mutation were more likely to have nonfunctioning tumors and PGL (P # .005 each). Local recurrence and distant metastases were more frequent in patients with SDHB mutation compared with patients without an SDHB mutation (47.6% vs 9.1% and 56.3% vs 9.1%, P < .001 each). Five of the 7 deaths occurred in patients with SDHB mutations (Table I) . Percent of tumor Requiring an open surgical approach was associated with a greater rate of locoregional recurrence (P < .001). Neither the tumor functional status nor the percent staining for Ki67 were associated with locoregional recurrence. There were no locoregional recurrences in any of the 7 patients with a Ki67% of 1-3%, nor the 5 patients who had Ki67% >3%. MI also was not associated with locoregional recurrence (P = .066). However, the mean MI was less in patients without locoregional recurrence compared with patients with locoregional recurrence (1.2 vs 4.7, respectively, P = .04). Only 2 patients with a MI $2 had locoregional recurrence.
Mean greatest tumor diameter for patients who did not have locoregional recurrence was less than the mean tumor diameter in patients who had locoregional recurrence (4.5 ± 0.5 cm, 7.6 ± 0.8 cm; P < .001; Table II ). Mean tumor diameter was less for patients without distant metastases (3.7 ± 0.3 cm, 7.7 ± 0.9 cm; P < .001). PGL and requiring an open operative approach were associated with distant metastases (P # .004 each). Neither the tumor functional status nor Ki67% and MI were associated with distant metastases (P $ .22 each; Table III) .
By logistic regression, only SDHB mutation status and tumor diameter were independent risk factors for locoregional recurrence and distant metastases (P # .004 each). Compared with patients with sporadic disease, patients with SDHB mutation and PC/PGL had a lesser DFI (89.8 months, 95% confidence interval [CI] 36.0-96.4 vs median not reached, P < .001). Patients with PGL had a lesser DFI compared with patients with PC (91.8 months, 95% CI, 38.4-96.4 vs median not reached, P = .044). Patients who required an open rather than a laparoscopic approach also had a lesser DFI (48.5 months, 95% CI, 16.0-103.0 vs median not reached, P < .001). There was no difference in median DFI between functional and nonfunctional tumors (89.8 months, 95% CI, 2-89.8 vs 103.0 months, 95% CI, 51.0-undefined, P = .11; Fig 2) . Larger tumor diameter was found to be associated with a lesser DFI (median not reached for <3.0 cm vs 96.4 months for 3.1-6.0 cm, 95% CI, 48.5-undefined vs 38.4 months for >6.1 cm 95% CI, 6.8-undefined, P < .001). Ki67% and MI were not associated with DFI (P $ .19 each; Fig 3) . In the Cox proportional hazards model analysis, SDHB mutation status and tumor diameter (<6.1 vs $6.1 cm) were found to be jointly associated with a lesser DFI with a hazard ratio of 16.2 (95% CI, 1.9-138.5, P = .011) and 15.4 (95% CI, 2.6-92.2, P = .003), respectively.
DISCUSSION
We performed a comprehensive analysis of clinical, biochemical, genetic, treatment, and histologic factors associated with patient outcome. We found that the presence of SDHB mutation and primary tumor size were the only 2 independent factors associated jointly with a lesser DFI. We found other variables were also associated with DFI and locoregional and distant disease by univariate analysis. Our study findings suggest that a prognostic/staging system for PC and PGL should include the SDHB mutation status and primary tumor size.
Our results demonstrating that SDHB mutation status is associated with younger age at presentation, PGL, local recurrence, distant metastases, and decreased survival are consistent with previous studies. 7, 16 The association of the primary tumor size with locoregional recurrence and distant metastases is also consistent with other studies. 9, 17 Our finding that SDHB mutation status and primary tumor size are more predictive of patient outcomes than Ki67% or MI suggests that histologic-based grading systems may not be as useful. We found that Ki67% and MI are not associated with locoregional recurrence or distant metastases, nor were they associated with SDHB mutation status and a lesser DFI.
We found an association between SDHB mutation, primary tumor size, requiring an open operative approach, PGL, and a lesser DFI. Requiring an open operative approach is most likely reflective of large, extra-adrenal, or locally invasive neoplasms but was not statistically significant in a multivariate analysis. Although an association between Ki67% staining and metastatic disease has been reported, only a limited number of cases were analyzed. 18 The grading system for adrenal PC and PGL score, which includes Ki67%, was based on a series of patients in which only 25% had metastatic disease and 8% of patients had an SDHB mutation.
One limitation of our study is a selection bias inherent in being a referral center for familial and aggressive cases of PC and PGL, which accounts for the large proportion of patients with SDHB mutations who may thus have closer postoperative surveillance as compared with patients with sporadic disease. The advantage to this referral pattern was the opportunity to examine a substantial number of samples from patients with SDHB mutations and aggressive malignancies. Our sample size did not allow for analysis of overall survival and the clinical and pathologic factors or subgroups of PC/PGL such as sporadic PC, SDHB PC, and SDHB PGL. Therefore, we cannot rule out the possibility that within $1 of these subgroups, there may be an association between Ki67% or MI and patient outcomes. In our study, the risk for an SDHB mutation or tumor >5 cm in diameter to have local recurrence and distant metastasis was extremely high. Given the association of an SDHB mutation and tumor size with greater rates of local recurrence and distant metastasis, any scoring system that does not take these factors into consideration may not predict the outcomes accurately nor identify high-risk patients who require closer surveillance or adjuvant therapy after operative treatment for PC/PGL. 19 Historically approximately 10% of PCs/PGLs were thought to be familial, but discovery of SDHx, MAX, and other mutations has increased this estimate to as high as 40%, with apparently sporadic cases also bearing somatic mutations when subjected to whole exome or next-generation sequencing. 20 As more is understood about the genetic basis of PC/PGL, the importance of mutation status on the natural history of PC/PGL and what diagnostic and localizing methods should be used in such cases of PC/PGL has become clearer. 20 For example, tumors in patients with SDHB mutations have unique metabolic and expression profiles. 21 Furthermore, diagnostic modalities appropriate for sporadic PC/PGL may not be effective in SDHB PC/PGL. 22 Therapeutic approaches directed at altered pathways in SDHB mutations can also be better applied with knowledge of mutation status and high likelihood of recurrence and metastases. 21, [23] [24] [25] Therefore, the importance of including mutation status as part of a grading/staging system is useful for prognosis as well as guiding therapy.
In conclusion, the results of our study support the concept that patients with SDHB mutations and large tumors are at very high risk for recurrence and distant metastases, and these patients should have close postoperative surveillance. Germline mutation status should be tested in all patients with PGL, as well as any young patient presenting with PC/PGL. Knowledge of SDHB status may be necessary to predict outcomes accurately to improve the care of patients with PC and abdominal PGL; SDHB status should be part of any clinically relevant prognostic scoring system. Combining SDHB status and size of the primary tumor may be the most accurate way to create a grading system that can be adopted widely.
Future studies are needed to determine if the incorporation of certain pathologic features, such as Ki67%, differentiation, or necrosis, may augment further the prognostic accuracy of genetic status and primary size. It is possible Ki67% may augment a grading system that includes mutation status and primary tumor size, but histologic data in isolation are not sufficient for a valuable grading/staging system, and in the setting of SDHB mutations, Ki67% may not be predictive of prognosis. 
Dr Quan-Yang Duh (San Francisco, CA): Very nice presentation and excellent data. I have a simple question for you. The SDHB mutation is a dichotomous variable. Obviously, you check to see whether they have it or they do not. Size is a continuous variable. So, can you tell me at what size you worry about the tumor, 6 centimeters, 5 centimeters, 4 centimeters? Because in my mind, if it is a paraganglioma, I worry about it anyway, whatever the size is, even a 3-centimeter, knowing or not their mutational status. But for the adrenal gland itself, for a regular pheo, I worry about it according to size. So I wonder after looking at all the data, can you give us some guidance about should I worry more when it is beyond 5 centimeters? Dr Yasmine Assadipour: We looked at the tumor size in 2 different methods of categorization. One was zero to 3, 3 to 6, and 6 and over. The other was under 5 and over 5. Even in under 5 and over 5, there is clearly a difference in recurrent metastases, and disease-free interval was over 5 centimeters. And under 3 centimeters, there is very low concern for those.
So I think a good cut-off would be 5 centimeters, based on our findings and other people's findings in previous studies, and 4 becomes kind of a gray zone. As you said, for any retroperitoneal paraganglioma regardless of the size, there is a high concern for local recurrence and distant metastases, but for adrenal pheochromocytomas, over 5 centimeters, I believe, is a good cut-off for being very concerned. So what is your recommendation now? Is there a size cut-off for which you approach a patient with an SDHB mutation and a paraganglioma for a laparoscopic or open procedure? Dr Yasmine Assadipour: Our general recommendation is that for adrenal pheochromocytoma over 6 centimeters, the concern for a rupture becomes higher, and therefore open approach may be recommended. The retroperitoneal paragangliomas, in general, unless they are quite small, and if they are noninvasive, we actually recommend an open approach. Again, this is not based on a randomized control study but just based on the fact that those retroperitoneal paragangliomas have such a high local recurrence rate. It may be that laparoscopic lymphadenectomy that you perform is not sufficient to really be clearing the disease as much as possible.
Dr Barry Inabnet (New York, NY): Congratulations on a great presentation. My question is about the Ki67 index. Many pathologists do not routinely measure that when assessing genopathology aside from ACC. Could you comment on why was GI neuroendocrine tumor Ki67 is such an important prognosticator for paragangliomas? In your analysis, it was not. And did you dissect that down and look at your Ki67 and size, and was that in any way related to the size of the tumor? In other words, in bigger tumors, was the Ki67 higher compared to smaller tumors? Very interesting.
Dr Yasmine Assadipour: That could be an interesting thing to look at it and that will be a great question. I will look into your second question. The first question is something that we all thought about a lot, because it was sort of not what we were expecting, and as you pointed out, it is sort of the exception to neuroendocrine tumors. I would hypothesize that because our cohort has so many patients with SDHB, that may be a reason why we did not come to the same conclusion that other papers have with Ki67 limited to pheochromocytomas, or the paper that Dr Kimura put out with a GAPP score of only 25% of the 163 samples were malignant and less than 8% were in the context of an SDHB mutation. So I would theorize that is because we had a majority of patients with the SDHB mutation.
Metastases are a combination of a lot of different factors, so obviously cell proliferation can help increase the number of cells that enter the circulation, but in terms of putting up microenvironments so that we would be able to take hold of the metastases, I think there are some other factors that had to come in to play there. So I would hypothesize that SDHB mutations come with a propensity to really be able to metastasize in a way that is not necessarily directly related to their Ki67 score, which is really the marker for cell proliferation.
Dr Nancy Perrier (Houston, TX): The new AJCC guidelines, the 8th edition that is coming out this summer, will include paraganglioma and pheochromocytomas for the first time, so congratulations to you and Electron and your group for bringing this to the table, because it will be part of our conversations this summer. In those new guidelines, the site of metastases has bearing on the survival, whether it is lung or bone, and I am sure you saw that in your own cohort. Would you comment on that? And would you also comment on why your group decided to specifically just look at SDH mutations instead of other mutations that we know have a bearing for prognosis, good or bad?
Dr Yasmine Assadipour: For the first part of your question, we do know that certain types of metastases are more impactful on survival than others.
I think what would have been interesting is if we had actually looked at the Ki67 and seen if we could relate it to different sites of metastases. I think another really interesting thing to do would be to look at a primary tumor and look at a metastasis and see if there is a difference in the Ki67 cell proliferation or not and if that could be related to the site of metastases, but we did not actually look at that in this study. That is a great question.
And your second question was why just SDH mutations. So we decided to stick with SDH mutations, because I was particularly interested in how aggressive these SDHB tumors could be, and they were affecting very young patients, and they were metastasizing even when they were quite small. So that was of particular interest to me. We had many patients that have VHL, MEN or their mutations, but because of the specific nature of how effective SDHB are, that is what really guided my interest, and my question was in terms of the Ki67, would we be fooling ourselves into thinking that a tumor that has a low Ki67 labeling, and that means that it is not particularly aggressive, and is that totally irrelevant in the setting of these mutations, because if it is, you do not want to be relying on that for patients if it is really only relevant to sporadic patients.
